[1]BioorganicandMedicinalChemistryLetters,2012,vol.22,p.4599-4604
[1]Patent:WO2019/243491,2019,A1.Locationinpatent:Page/Pagecolumn76
[1]CurrentPatentAssignee:CANCERTHERAPEUTICSCRCPTYLTD-WO2019/243491,2019,A1Locationinpatent:Page/Pagecolumn76-77
[1]Patent:WO2019/243491,2019,A1
1311197-87-1
261763-33-1
63762-78-7
1033202-20-8
951885-64-6
1204176-29-3
10362-82-0 | ALPHA-METHYLSTYRENE-D10 | AA008SXO | MFCD01317459
1130-93-4 | 7-Methyl-1,2,3,4-tetrahydrocyclopenta[b]indole | AA008T5Z | MFCD05625697
1042672-97-8 | IRAK inhibitor 6 | AA008TE9 | MFCD22124485
108963-70-8 | D-Lys(Z)-Pro-Arg-pNA (diacetate) | AA008TJ1 | MFCD29472230
1123837-84-2 | Sitravatinib | AA008TMR | MFCD28502181
109029-96-1 | 2-Chloro-5-(morpholinosulfonyl)benzoic acid | AA008TVC | MFCD00492872
1173052-99-7 | N-[4-Chloro-3-(morpholin-4-ylsulfonyl)phenyl]-2-(methylamino)acetamide hydrochloride | AA008U3Y | MFCD08448134
1184917-16-5 | 4-Bromo-2,5-dichloropyridine | AA008UDS | MFCD12911586
1204298-58-7 | tert-Butyl 3-amino-1h-indazole-1-carboxylate | AA008UNA | MFCD12827767
118358-38-6 | FMOC-L-SER(BETA-D-GLCAC4)-OH | AA008UY4 | MFCD03452820